Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1954 3
1955 4
1956 1
1957 3
1959 1
1960 1
1961 1
1962 3
1963 3
1964 12
1965 3
1966 9
1967 9
1968 7
1969 5
1970 3
1971 1
1972 3
1973 2
1974 1
1975 3
1976 1
1977 7
1978 2
1979 2
1980 1
1981 1
1982 2
1983 1
1984 2
1985 4
1986 7
1987 4
1988 4
1989 6
1990 6
1991 6
1992 4
1993 6
1994 10
1995 11
1996 10
1997 6
1998 3
1999 6
2000 4
2001 5
2002 8
2003 6
2004 15
2005 16
2006 17
2007 17
2008 24
2009 16
2010 10
2011 16
2012 21
2013 23
2014 21
2015 19
2016 29
2017 33
2018 27
2019 37
2020 42
2021 49
2022 57
2023 56
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

712 results

Results by year

Filters applied: . Clear all
Page 1
Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions.
Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, Laplant Q, Graham A, Lutter M, Lagace DC, Ghose S, Reister R, Tannous P, Green TA, Neve RL, Chakravarty S, Kumar A, Eisch AJ, Self DW, Lee FS, Tamminga CA, Cooper DC, Gershenfeld HK, Nestler EJ. Krishnan V, et al. Among authors: chakravarty s. Cell. 2007 Oct 19;131(2):391-404. doi: 10.1016/j.cell.2007.09.018. Cell. 2007. PMID: 17956738 Free article.
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ. McInnes IB, et al. Among authors: chakravarty sd. Arthritis Rheumatol. 2022 Mar;74(3):475-485. doi: 10.1002/art.42010. Epub 2022 Feb 7. Arthritis Rheumatol. 2022. PMID: 34719872 Free PMC article. Clinical Trial.
Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.
Sutton HJ, Aye R, Idris AH, Vistein R, Nduati E, Kai O, Mwacharo J, Li X, Gao X, Andrews TD, Koutsakos M, Nguyen THO, Nekrasov M, Milburn P, Eltahla A, Berry AA, Kc N, Chakravarty S, Sim BKL, Wheatley AK, Kent SJ, Hoffman SL, Lyke KE, Bejon P, Luciani F, Kedzierska K, Seder RA, Ndungu FM, Cockburn IA. Sutton HJ, et al. Among authors: chakravarty s. Cell Rep. 2021 Feb 9;34(6):108684. doi: 10.1016/j.celrep.2020.108684. Cell Rep. 2021. PMID: 33567273 Free PMC article. Clinical Trial.
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A, Chakravarty SD, Parackal A, Karyekar CS, Nair S, Boehncke WH, Ritchlin C. Mease PJ, et al. Among authors: chakravarty sd. Rheumatology (Oxford). 2021 May 14;60(5):2109-2121. doi: 10.1093/rheumatology/keab119. Rheumatology (Oxford). 2021. PMID: 33844022 Free PMC article.
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.
Mease PJ, McInnes IB, Tam LS, Rajalingam R, Peterson S, Hassan F, Chakravarty SD, Contré C, Armstrong A, Boehncke WH, Ritchlin C. Mease PJ, et al. Among authors: chakravarty sd. Rheumatology (Oxford). 2023 Apr 3;62(4):1417-1425. doi: 10.1093/rheumatology/keac500. Rheumatology (Oxford). 2023. PMID: 36102818 Free PMC article.
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.
Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU. Haberman RH, et al. Among authors: chakravarty sd. BMJ Open. 2022 Dec 23;12(12):e063650. doi: 10.1136/bmjopen-2022-063650. BMJ Open. 2022. PMID: 36564123 Free PMC article.
Editorial: Women in neurogenesis.
Pérez-Martín M, Chakravarty S. Pérez-Martín M, et al. Among authors: chakravarty s. Front Neurosci. 2023 Sep 14;17:1285728. doi: 10.3389/fnins.2023.1285728. eCollection 2023. Front Neurosci. 2023. PMID: 37790592 Free PMC article. No abstract available.
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Østergaard M, Baraliakos X. Gladman DD, et al. Among authors: chakravarty sd. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y. Trials. 2022. PMID: 36064592 Free PMC article.
Cronkhite-Canada syndrome.
Vashistha N, Chakravarty S, Singhal D. Vashistha N, et al. Among authors: chakravarty s. Gastrointest Endosc. 2017 Nov;86(5):922-923. doi: 10.1016/j.gie.2017.05.028. Epub 2017 May 30. Gastrointest Endosc. 2017. PMID: 28576394 No abstract available.
Kirigami-Inspired Biodesign for Applications in Healthcare.
Brooks AK, Chakravarty S, Ali M, Yadavalli VK. Brooks AK, et al. Among authors: chakravarty s. Adv Mater. 2022 May;34(18):e2109550. doi: 10.1002/adma.202109550. Epub 2022 Mar 13. Adv Mater. 2022. PMID: 35073433 Review.
712 results